Elanco Animal Health Inc(ELAN)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .

Elanco Animal Health Inc (ELAN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELAN at 48.7/100 on a 32-signal composite quality model, placing it at rank #1,703 of 2,961 stocks — the bottom half of the AI-ranked universe. ELAN scores in the top quartile across earnings quality (90.8), revenue scale (77.8). Areas of concern include profitability (22.4) and balance sheet strength (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Elanco Animal Health Inc reports quarterly revenue of $1.4B, net income of $54.0M, free cash flow of $244.0M. Top institutional holders of ELAN by reported 13-F value include DODGE & COX, FMR, BlackRock, based on the most recent SEC filings. ELAN trades on the NYSE exchange and files with the SEC under CIK 1739104. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELAN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elanco Animal Health Inc directly from SEC EDGAR.

AI Quality Score

48.7/100

AI Rank

#1,703

Revenue

$1.4B

Net Income

$54.0M

Free Cash Flow

$244.0M

ELAN key financials by period

Elanco Animal Health Inc reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodFormRevenueNet incomeOperating margin
FY 202510-K$4.7B$-232.0M-4.8%
FY 202410-K$4.4B$338.0M11.0%
FY 202310-K$4.4B$-1.2B-27.1%
FY 202210-K$4.4B$-78.0M-1.6%
FY 202110-K$4.8B$-483.0M-12.0%
FY 202010-K$3.3B$-574.0M-20.7%

Institutions holding ELAN

Institutional investors reporting a position in Elanco Animal Health Inc on SEC Form 13F.
InstitutionSharesValueReported
DODGE & COX67,397,025$1.7B2026-06-30
FMR56,948,819$1.4B2026-06-30
BlackRock48,849,973$1.2B2026-06-30
PRIMECAP MANAGEMENT45,445,012$1.1B2026-06-30
T. Rowe Price Investment Management28,750,719$707.6M2026-06-30
DIMENSIONAL FUND ADVISORS25,417,271$625.5M2026-06-30
VANGUARD PORTFOLIO MANAGEMENT22,672,312$558.0M2026-06-30
VANGUARD CAPITAL MANAGEMENT22,607,532$556.4M2026-06-30
STATE STREET16,063,046$395.3M2026-06-30
Winslow Capital Management13,511,127$332.5M2026-06-30
ELAN

Elanco Animal Health Inc

ELAN
NYSELarge CapHealthcare

13F Pro Quality Score

48.7/100

Rank #1,703 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

44.5/100

Profitability

22.4/100

Balance Sheet

30.0/100

Earnings Quality

90.8/100

Free Cash Flow

49.1/100

Institutional Flow

36.2/100

Revenue Scale

77.8/100

Dilution Risk

47.4/100

Price Chart

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.
Reading the latest SEC filing… (first load can take ~20s)

Key Metrics

Revenue

Q2 2026
EDGAR

$1.37B

Net Income

Q2 2026
EDGAR

$54.00M

EPS (Diluted)

Q2 2026
EDGAR

$0.11

ROIC

Q2 2026
EDGAR

2.1%

Free Cash Flow

Q2 2026
EDGAR

$244.00M

Debt/Equity

Q2 2026
EDGAR

0.59

Top Institutional Holders

as of Q2 2026
$13.97B total

Financial Trends

Revenue & Net Income

Earnings Per Share

Loading ratio trend…